메뉴 건너뛰기




Volumn 20, Issue 12, 2015, Pages 1455-1463

Precision medicine in oncology drug development: A pharma perspective

Author keywords

[No Author keywords available]

Indexed keywords

ACCURACY; BREAST CANCER; CLINICAL TRIAL (TOPIC); COLORECTAL CANCER; DIAGNOSTIC PROCEDURE; DRUG APPROVAL; DRUG DEVELOPMENT; DRUG MARKETING; HOSPITAL PATIENT; HUMAN; INCIDENCE; MEDICINE; NON PROFIT ORGANIZATION; NON SMALL CELL LUNG CANCER; ONCOLOGY; PATIENT SELECTION; PHASE 2 CLINICAL TRIAL (TOPIC); PUBLIC-PRIVATE PARTNERSHIP; REVIEW; STOMACH CANCER; STUDY DESIGN; SURVIVAL; DRUG INDUSTRY; NEOPLASMS; PERSONALIZED MEDICINE; PROCEDURES;

EID: 84949485483     PISSN: 13596446     EISSN: 18785832     Source Type: Journal    
DOI: 10.1016/j.drudis.2015.10.005     Document Type: Review
Times cited : (22)

References (52)
  • 1
    • 79952284127 scopus 로고    scopus 로고
    • Hallmarks of cancer: The next generation
    • D. Hanahan, and R.A. Weinberg Hallmarks of cancer: the next generation Cell 144 2011 646 674
    • (2011) Cell , vol.144 , pp. 646-674
    • Hanahan, D.1    Weinberg, R.A.2
  • 2
    • 84905029258 scopus 로고    scopus 로고
    • Comprehensive molecular profiling of lung adenocarninoma
    • The Cancer Genome Atlas Research Network
    • The Cancer Genome Atlas Research Network Comprehensive molecular profiling of lung adenocarninoma Nature 511 2014 543 550
    • (2014) Nature , vol.511 , pp. 543-550
  • 3
    • 84866894408 scopus 로고    scopus 로고
    • Comprehensive genomic characterization of squamous cell lung cancers
    • Cancer Genome Atlas Research Network
    • Cancer Genome Atlas Research Network Comprehensive genomic characterization of squamous cell lung cancers Nature 489 2012 519 925
    • (2012) Nature , vol.489 , pp. 519-925
  • 4
    • 84907270779 scopus 로고    scopus 로고
    • Comprehensive molecular characterization of gastric adenocarcinoma
    • Cancer Genome Atlas Research Network
    • Cancer Genome Atlas Research Network Comprehensive molecular characterization of gastric adenocarcinoma Nature 513 2014 202 209
    • (2014) Nature , vol.513 , pp. 202-209
  • 5
    • 84863922124 scopus 로고    scopus 로고
    • Comprehensive molecular characterization of human colon and rectal cancer
    • Cancer Genome Atlas Network
    • Cancer Genome Atlas Network Comprehensive molecular characterization of human colon and rectal cancer Nature 487 2012 330 337
    • (2012) Nature , vol.487 , pp. 330-337
  • 6
    • 84877028141 scopus 로고    scopus 로고
    • Comprehensive molecular portraits of human breast tumours
    • Cancer Genome Atlas Network
    • Cancer Genome Atlas Network Comprehensive molecular portraits of human breast tumours Nature 490 2012 61 70
    • (2012) Nature , vol.490 , pp. 61-70
  • 7
    • 77953930730 scopus 로고    scopus 로고
    • Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR
    • M. Maemondo, and et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR N. Engl. J. Med. 362 2010 2380 2388
    • (2010) N. Engl. J. Med. , vol.362 , pp. 2380-2388
    • Maemondo, M.1
  • 8
    • 84928739294 scopus 로고    scopus 로고
    • AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer
    • P.A. Jänne, and et al. AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer N. Engl. J. Med. 372 2015 1689 1699
    • (2015) N. Engl. J. Med. , vol.372 , pp. 1689-1699
    • Jänne, P.A.1
  • 9
    • 84903547236 scopus 로고    scopus 로고
    • Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: A preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial
    • J. Ledermann, and et al. Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial Lancet 15 2014 852 861
    • (2014) Lancet , vol.15 , pp. 852-861
    • Ledermann, J.1
  • 10
    • 84879071011 scopus 로고    scopus 로고
    • Crizotinib versus chemotherapy in advanced ALK-positive lung cancer
    • A.T. Shaw, and et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer N. Engl. J. Med. 368 2013 2385 2394
    • (2013) N. Engl. J. Med. , vol.368 , pp. 2385-2394
    • Shaw, A.T.1
  • 11
    • 84863116743 scopus 로고    scopus 로고
    • Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib
    • J.A. Sosman, and et al. Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib N. Engl. J. Med. 366 2012 707 714
    • (2012) N. Engl. J. Med. , vol.366 , pp. 707-714
    • Sosman, J.A.1
  • 12
    • 80053539103 scopus 로고    scopus 로고
    • Adjuvant trastuzumab in HER2-positive breast cancer
    • D. Slamon, and et al. Adjuvant trastuzumab in HER2-positive breast cancer N. Engl. J. Med. 365 2011 1273 1283
    • (2011) N. Engl. J. Med. , vol.365 , pp. 1273-1283
    • Slamon, D.1
  • 13
    • 0037103424 scopus 로고    scopus 로고
    • Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors
    • G.D. Demetri, and et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors N. Engl. J. Med. 347 2002 472 480
    • (2002) N. Engl. J. Med. , vol.347 , pp. 472-480
    • Demetri, G.D.1
  • 14
    • 84900829967 scopus 로고    scopus 로고
    • Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs
    • M.G. Kris, and et al. Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs JAMA 311 2014 1998 2006
    • (2014) JAMA , vol.311 , pp. 1998-2006
    • Kris, M.G.1
  • 15
    • 2342471392 scopus 로고    scopus 로고
    • Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib
    • T.J. Lynch, and et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib N. Engl. J. Med. 350 2004 2129 2139
    • (2004) N. Engl. J. Med. , vol.350 , pp. 2129-2139
    • Lynch, T.J.1
  • 16
    • 2342624080 scopus 로고    scopus 로고
    • EGFR mutations in lung cancer: Correlation with clinical response to gefitinib therapy
    • J.G. Paez, and et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy Science 304 2004 1497 1500
    • (2004) Science , vol.304 , pp. 1497-1500
    • Paez, J.G.1
  • 17
    • 69949162760 scopus 로고    scopus 로고
    • Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma
    • T.S. Mok, and et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma N. Engl. J. Med. 361 2009 947 957
    • (2009) N. Engl. J. Med. , vol.361 , pp. 947-957
    • Mok, T.S.1
  • 18
    • 79960702788 scopus 로고    scopus 로고
    • Biomarker analyses and final overall survival results from a Phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS)
    • M. Fukuoka, and et al. Biomarker analyses and final overall survival results from a Phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS) J. Clin. Oncol. 29 2011 2866 2874
    • (2011) J. Clin. Oncol. , vol.29 , pp. 2866-2874
    • Fukuoka, M.1
  • 19
    • 56249109644 scopus 로고    scopus 로고
    • Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): A randomised Phase III trial
    • E.S. Kim, and et al. Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised Phase III trial Lancet 372 2008 1809 1818
    • (2008) Lancet , vol.372 , pp. 1809-1818
    • Kim, E.S.1
  • 20
    • 77649222572 scopus 로고    scopus 로고
    • Molecular predictors of outcome with gefitinib and docetaxel in previously treated non-small-cell lung cancer: Data from the randomized Phase III INTEREST trial
    • J-Y. Douillard, and et al. Molecular predictors of outcome with gefitinib and docetaxel in previously treated non-small-cell lung cancer: data from the randomized Phase III INTEREST trial J. Clin. Oncol. 28 2010 744 752
    • (2010) J. Clin. Oncol. , vol.28 , pp. 744-752
    • Douillard, J.-Y.1
  • 21
    • 34547638047 scopus 로고    scopus 로고
    • Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer
    • M. Soda, and et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer Nature 448 2007 561 566
    • (2007) Nature , vol.448 , pp. 561-566
    • Soda, M.1
  • 22
    • 77955174967 scopus 로고    scopus 로고
    • Clinical activity of the oral ALK inhibitor PF-02341066 in ALK-positive patients with non-small cell lung cancer (NSCLC)
    • Y. Bang, and et al. Clinical activity of the oral ALK inhibitor PF-02341066 in ALK-positive patients with non-small cell lung cancer (NSCLC) J. Clin. Oncol. 28 Suppl. 18 2010 3
    • (2010) J. Clin. Oncol. , vol.28 , pp. 3
    • Bang, Y.1
  • 23
    • 78049425319 scopus 로고    scopus 로고
    • Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer
    • E.L. Kwak, and et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer N. Engl. J. Med. 363 2010 1693 1703
    • (2010) N. Engl. J. Med. , vol.363 , pp. 1693-1703
    • Kwak, E.L.1
  • 24
    • 84872569905 scopus 로고    scopus 로고
    • Phase III study of crizotinib versus pemetrexed or docetaxel chemotherapy in patients with advanced ALK-positive non-small cell lung cancer (NSCLC)
    • Abstr. LBA1 PR
    • A.T. Shaw, and et al. Phase III study of crizotinib versus pemetrexed or docetaxel chemotherapy in patients with advanced ALK-positive non-small cell lung cancer (NSCLC) Eur. Soc. Med. Oncol. Meet 2012 Abstr. LBA1 PR
    • (2012) Eur. Soc. Med. Oncol. Meet
    • Shaw, A.T.1
  • 25
    • 84949502323 scopus 로고    scopus 로고
    • Vysis ALK BAP FISH Probe Kit instructions. Available at
    • Vysis ALK BAP FISH Probe Kit instructions. Available at: http://www.accessdata.fda.gov/cdrh-docs/pdf11/P110012c.pdf
  • 26
    • 84949524462 scopus 로고    scopus 로고
    • FDA Drug Approvals And Databases. Available at
    • FDA Drug Approvals And Databases. Available at: http://www.fda.gov/Drugs/InformationOnDrugs/
  • 27
    • 84949484036 scopus 로고    scopus 로고
    • FDA List of Cleared or Approved Companion Diagnostic Devices (In Vitro and Imaging Tools). Available at
    • FDA List of Cleared or Approved Companion Diagnostic Devices (In Vitro and Imaging Tools). Available at: http://www.fda.gov/MedicalDevices/ProductsandMedicalProcedures/InVitroDiagnostics/ucm301431.htm
  • 28
    • 84949485423 scopus 로고    scopus 로고
    • FDA Nucleic Acid Based Tests. Available at
    • FDA Nucleic Acid Based Tests. Available at: http://www.fda.gov/MedicalDevices/ProductsandMedicalProcedures/InVitroDiagnostics/ucm330711.htm
  • 29
    • 84949522424 scopus 로고    scopus 로고
    • European Medicines Agency (EMA) approvals. Available at
    • European Medicines Agency (EMA) approvals. Available at: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/landing/human-medicines-regulatory.jsp&mid
  • 30
    • 84949499089 scopus 로고    scopus 로고
    • Report The Academy of Medical Sciences. Available at
    • Report The Academy of Medical Sciences. Available at: https://www.acmedsci.ac.uk/viewFile/51e915f9f09fb.pdf
  • 31
    • 84949505797 scopus 로고    scopus 로고
    • Report Association of the British Pharmaceutical Industry (ABPI). Available at
    • Report Association of the British Pharmaceutical Industry (ABPI). Available at: http://www.abpi.org.uk/our-work/library/medical-disease/Documents/strat-med.pdf
  • 32
    • 79957857433 scopus 로고    scopus 로고
    • The BATTLE trial: Personalizing therapy for lung cancer
    • E.S. Kim, and et al. The BATTLE trial: personalizing therapy for lung cancer Cancer Discov. 1 2011 44 53
    • (2011) Cancer Discov. , vol.1 , pp. 44-53
    • Kim, E.S.1
  • 33
    • 84865191389 scopus 로고    scopus 로고
    • Chemotherapy response and recurrence-free survival in neoadjuvant breast cancer depends on biomarker profiles: Results from the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657)
    • L.J. Esserman, and et al. Chemotherapy response and recurrence-free survival in neoadjuvant breast cancer depends on biomarker profiles: results from the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657) Breast Cancer Res. Treat. 132 2012 1049 1062
    • (2012) Breast Cancer Res. Treat. , vol.132 , pp. 1049-1062
    • Esserman, L.J.1
  • 34
    • 84856522259 scopus 로고    scopus 로고
    • Pathologic complete response predicts recurrence-free survival more effectively by cancer subset: Results from the I-SPY 1 TRIAL - CALGB 150007/150012, ACRIN 6657
    • L.J. Esserman, and et al. Pathologic complete response predicts recurrence-free survival more effectively by cancer subset: results from the I-SPY 1 TRIAL - CALGB 150007/150012, ACRIN 6657 J. Clin. Oncol. 30 2012 3242 3249
    • (2012) J. Clin. Oncol. , vol.30 , pp. 3242-3249
    • Esserman, L.J.1
  • 35
    • 84862501734 scopus 로고    scopus 로고
    • Locally advanced breast cancer: MR imaging for prediction of response to neoadjuvant chemotherapy - Results from ACRIN 6657/I-SPY TRIAL
    • N.M. Hylton, and et al. Locally advanced breast cancer: MR imaging for prediction of response to neoadjuvant chemotherapy - results from ACRIN 6657/I-SPY TRIAL Radiology 263 2012 663 672
    • (2012) Radiology , vol.263 , pp. 663-672
    • Hylton, N.M.1
  • 36
    • 84865188320 scopus 로고    scopus 로고
    • Locally advanced breast cancers are more likely to present as interval cancers: Results from the I-SPY 1 TRIAL (CALGB 150007/150012, ACRIN 6657, InterSPORE Trial)
    • C. Lin, and et al. Locally advanced breast cancers are more likely to present as interval cancers: results from the I-SPY 1 TRIAL (CALGB 150007/150012, ACRIN 6657, InterSPORE Trial) Breast Cancer Res. Treat. 132 2012 871 879
    • (2012) Breast Cancer Res. Treat. , vol.132 , pp. 871-879
    • Lin, C.1
  • 37
    • 84949510980 scopus 로고    scopus 로고
    • MATRIX National Lung Cancer Trial, Cancer Research, UK. Available at
    • MATRIX National Lung Cancer Trial, Cancer Research, UK. Available at: http://scienceblog.cancerresearchuk.org/2014/04/17/stratified-medicine-and-the-lung-cancer-matrix-trial-part-of-a-cancer-care-revolution/
  • 38
    • 84949512475 scopus 로고    scopus 로고
    • Lung-MAP, Lung Master Protocol, Friends of Cancer Research, US. Available at
    • Lung-MAP, Lung Master Protocol, Friends of Cancer Research, US. Available at: http://www.focr.org/lung-map
  • 39
    • 84927177712 scopus 로고    scopus 로고
    • The AURORA initiative for metastatic breast cancer
    • D. Zardavas, and et al. The AURORA initiative for metastatic breast cancer Br. J. Cancer 111 2014 1881 1887
    • (2014) Br. J. Cancer , vol.111 , pp. 1881-1887
    • Zardavas, D.1
  • 40
    • 84949524298 scopus 로고    scopus 로고
    • Japan National Cancer Centre. Available at
    • Japan National Cancer Centre. Available at: http://www.ncc.go.jp/en/index.html
  • 41
    • 84949500709 scopus 로고    scopus 로고
    • EORTC, Colorectal Cancer Screening Platform, SPECTAColor. Available at
    • EORTC, Colorectal Cancer Screening Platform, SPECTAColor. Available at: http://spectacolor.eortc.org/
  • 42
    • 84949500407 scopus 로고    scopus 로고
    • EORTC, SPECTALung Available at
    • EORTC, SPECTALung Available at: http://www.eortc.org/news/eortc-through-spectalung-participates-in-european-consortium-validating-blood-based-cancer-biomarkers/
  • 43
    • 84949525401 scopus 로고    scopus 로고
    • National Cancer Institute (NCI), US, NCI-MATCH (Molecular Analysis for Therapy Choice). Available at
    • National Cancer Institute (NCI), US, NCI-MATCH (Molecular Analysis for Therapy Choice). Available at: http://www.cancer.gov/researchandfunding/areas/clinical-trials/nctn/match
  • 44
    • 84885021119 scopus 로고    scopus 로고
    • Considerations for the successful co-development of targeted cancer therapies and companion diagnostics
    • J. Fridlyand, and et al. Considerations for the successful co-development of targeted cancer therapies and companion diagnostics Nat. Rev. Drug. Discov. 12 2013 743 755
    • (2013) Nat. Rev. Drug. Discov. , vol.12 , pp. 743-755
    • Fridlyand, J.1
  • 45
    • 84949514097 scopus 로고    scopus 로고
    • Shaw, A.T. The Crizotinib Story: From Target to FDA Approval and Beyond. InforMEDical report. Available at
    • Shaw, A.T. The Crizotinib Story: From Target to FDA Approval and Beyond. InforMEDical report. Available at: http://www.informedicalcme.com/lucatoday/crizotinib-story-from-target-to-fda-approval/
  • 46
    • 84906273146 scopus 로고    scopus 로고
    • Crizotinib: A comprehensive review
    • A. Sahu, and et al. Crizotinib: a comprehensive review South Asian J. Cancer 2 2013 91 97
    • (2013) South Asian J. Cancer , vol.2 , pp. 91-97
    • Sahu, A.1
  • 47
    • 84949497802 scopus 로고    scopus 로고
    • United States, Food and Drug Administration Safety and Innovation Act (FDASIA) Section 902; Breakthrough Therapy Designation. Available at.
    • United States, Food and Drug Administration Safety and Innovation Act (FDASIA) Section 902; Breakthrough Therapy Designation. Available at: http://www.fda.gov/RegulatoryInformation/Legislation/SignificantAmendmentstotheFDCAct/FDASIA/ucm329491.htm.
  • 48
    • 84896957081 scopus 로고    scopus 로고
    • Ceritinib in ALK-rearranged non-small-cell lung cancer
    • A.T. Shaw, and et al. Ceritinib in ALK-rearranged non-small-cell lung cancer N. Engl. J. Med. 370 2014 1189 1197
    • (2014) N. Engl. J. Med. , vol.370 , pp. 1189-1197
    • Shaw, A.T.1
  • 49
    • 84878347085 scopus 로고    scopus 로고
    • CH5424802 (RO5424802) for patients with ALK-rearranged advanced non-small-cell lung cancer (AF-001JP study): A single-arm, open-label, phase 1-2 study
    • T. Seta, and et al. CH5424802 (RO5424802) for patients with ALK-rearranged advanced non-small-cell lung cancer (AF-001JP study): a single-arm, open-label, phase 1-2 study Lancet Oncol. 14 2013 590 598
    • (2013) Lancet Oncol. , vol.14 , pp. 590-598
    • Seta, T.1
  • 50
    • 84899489162 scopus 로고    scopus 로고
    • Direct-to-consumer genetic testing and personal genomics services: A review of recent empirical studies
    • J.S. Roberts, and J. Ostergren Direct-to-consumer genetic testing and personal genomics services: a review of recent empirical studies Curr. Genet. Med. Rep. 1 2013 182 200
    • (2013) Curr. Genet. Med. Rep. , vol.1 , pp. 182-200
    • Roberts, J.S.1    Ostergren, J.2
  • 51
    • 84949508567 scopus 로고    scopus 로고
    • Cure Forward Available at
    • Cure Forward Available at: http://cureforward.com/
  • 52
    • 84949516420 scopus 로고    scopus 로고
    • Foundation Medicine, Connect - Patients and Caregivers. Available at
    • Foundation Medicine, Connect - Patients and Caregivers. Available at: http://www.mycancerisunique.com/


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.